Intervention not reported
Any adverse events · informal caregivers of people affected by cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any adverse events · individuals with cancer (patients)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any depression Multiple measures used. CES‐D (Blanchard 1996; Kozachik 2001; Kuijer 2004; Kurtz 2005; McCorkle 2007). POMS Depression subscale (Bultz 2000; Campbell 2007). HADS‐D (Nicolaisen 2018; Robertson 2016). Additional study (reported in com... · informal caregivers of people affected by cancer
1 finding from 1 review
Intervention not reported
Any depression Multiple measures used. CES‐D (Blanchard 1996;McCorkle 2007). POMS Depression subscale (Bultz 2000). HADS‐D (Nicolaisen 2018; Robertson 2016). Higher scores indicate higher levels of depression. Folllow‐up: Three to six months post‐... · informal caregivers of people affected by cancer
1 finding from 1 review
Intervention not reported
Any anxiety STAI‐S (Blanchard 1996). POMS Anxiety subscale (Bultz 2000; Campbell 2007). HADS‐A (Nicolaisen 2018; Robertson 2016). Additional study (reported in comments section): SCL‐90‐R Anxiety subscale (Heinrich 1985). Higher scores indicate hi... · informal caregivers of people affected by cancer
1 finding from 1 review
Intervention not reported
Any anxiety STAI‐S (Blanchard 1996). POMS Anxiety subscale (Bultz 2000). HADS‐A (Nicolaisen 2018; Robertson 2016). Higher scores indicate higher levels of anxiety. · informal caregivers of people affected by cancer
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with cariprazine (1… probably leads to higher dropouts ‐ any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
> 50% reduction in depressive symptoms · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with cariprazine (1… probably leads to higher response (≥ 50% improvement in MADRS score) ‐ any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with cariprazine (1… showed no clear difference in remission (MADRS total score ≤ 10) ‐ any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… showed no clear difference in dropouts ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine… probably leads to higher remission (MADRS score ≤ 8/HAM‐D score ≤ 7) ‐ Any dose compared with augmentation of current antidepressant (various) with placebo (moderate certainty).
1 finding from 1 review
Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Criminal activity ‐ Re‐arrests · drug‐using women offenders with co‐occurring mental health problems
Therapeutic community and aftercare showed no clear difference in re‐arrest for any type of crime compared with cognitive behavioural skills (low certainty).
1 finding from 1 review